Article Sidebar

PDF (Tiếng Việt)
Published: 2026-08-25
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v205i8.5447
Issue
Vol. 205 No. 8 (2026)
Section
Các bài báo
How to Cite
Thăng, V. H., Đại, N. X., Hoàn, C. Q., Tâm, T. T., Hoàng Anh, N. ., & Tuấn Anh, P. . (2026). Treatment outcomes of subsequent-line Regorafenib in patients with advanced hepatocellular carcinoma. Journal of Medical Research, 205(8), 457-465. https://doi.org/10.52852/tcncyh.v205i8.5447

Treatment outcomes of subsequent-line Regorafenib in patients with advanced hepatocellular carcinoma

Vu Hong Thang, Nguyen Xuan Dai, Chu Quoc Hoan, Tran Thanh Tam, Nguyen Hoang Anh, Pham Tuan Anh

Main Article Content

Abstract

This retrospective combined with prospective descriptive study was conducted on 61 patients with advanced hepatocellular carcinoma treated with Regorafenib at K Hospital from August 2024 to April 2026. The objective response rate and disease control rate in the overall population were 3.3% and 18.0%, respectively. The median progression-free survival and overall survival calculated from the initiation of Regorafenib were 3.0 and 6.4 months, respectively. Impaired liver function (Child-Pugh B/C) and severe portal vein tumor thrombus (Vp3/Vp4) were independent adverse prognostic factors for overall survival. The most common adverse event was hand-foot skin reaction (21.3%), with the majority being mild. For patients with hepatocellular carcinoma who progressed after previous systemic therapies, subsequent treatment with Regorafenib in a selected population with preserved liver function demonstrated a safety profile and improved overall survival in real-world clinical practice in Vietnam.

Article Details

Keywords

Hepatocellular carcinoma, Regorafenib, subsequent-line therapy, prognostic factors

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
3. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66.
4. Kim YJ, Galle PR, Merle P, et al. Real-world efficacy and safety of regorafenib in patients with hepatocellular carcinoma: the REFINE observational study. Liver Cancer. 2022;11(6):539-550.
5. Yau T, Park JW, Finn RS, et al. Lenvatinib or sorafenib in hepatocellular carcinoma: A Chinese dataset from the global phase 3 REFLECT trial. Chin Clin Oncol. 2021;10(1):5.
6. Ogasawara S, Ooka Y, Koroki K, et al. Real-world evidence of regorafenib for patients with advanced hepatocellular carcinoma. Liver Cancer. 2020;9(5):543-558.
7. Yoo C, Byeon S, Bang Y, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver Int. 2020;40(9):2263-2271.
8. Komatsu S, Kamohara Y, Sato Y, et al. Survival benefit of regorafenib in patients with advanced hepatocellular carcinoma with macroscopic vascular invasion. Oncology Letters. 2021;99(3):1-9.
9. Kudo M. A new era of systemic therapy for hepatocellular carcinoma: Optimizing sequential and combinatorial therapies. Liver Cancer. 2019;8(5):327-340.
10. Teufel M, Seidel H, Köchert K, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019;156(6):1731-1741